^
    1d
    DARATALL-VHR: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD38 (CD38 Molecule)
    |
    cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1d
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    2d
    Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia. (PubMed, EJHaem)
    Both primary patient and Ba/F3 cells carrying TPR::ABL2 exhibited kinase activation and sensitivity to tyrosine kinase inhibitors (TKIs). This study expands the repertoire of ABL2 fusions identified in ALL and supports the incorporation of TKIs into T-ALL treatment regimens to improve outcomes for this subtype.
    Journal
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase) • TPR (Translocated Promoter Region)
    |
    ABL2 fusion
    |
    Scemblix (asciminib)
    2d
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    2d
    Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Baylor College of Medicine | Initiation date: Dec 2025 --> Jun 2026
    Trial initiation date
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide
    3d
    Targeting menin in T-lineage acute lymphoblastic leukemia. (PubMed, Mol Cancer Ther)
    We tested menin inhibitors (ziftomenib, revumenib, VTP-50469) in 14 primary T-ALL samples and 8 cell lines, representing HOXA-high and HOXA-low genotypes. In conclusion, a subset of T-ALL, defined by high p-MEF2C S222, is sensitive to menin inhibition. Combining ziftomenib with CDK or ERK inhibition offers synergistic efficacy, supporting biomarker-driven clinical trials of this strategy in relapsed/refractory T-ALL.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • MEIS1 (Meis Homeobox 1) • CDK1 (Cyclin-dependent kinase 1) • MEF2C (Myocyte Enhancer Factor 2C)
    |
    Revuforj (revumenib) • Komzifti (ziftomenib) • VTP-50469
    7d
    Ferroptosis Induction by Purple Sweet Potato Anthocyanins in T-cell Acute Lymphoblastic Leukemia: Combined Molecular Docking, In Vitro, and In Vivo Evidence. (PubMed, Front Biosci (Landmark Ed))
    This study provides the first evidence that PSPAs induce ferroptosis in T-ALL through modulation of the SLC7A11/GPX4 pathway. These findings reveal new mechanistic insights into ferroptosis in T-ALL and highlight PSPAs as safe, naturally derived therapeutic agents with promising therapeutic potential for leukemia.
    Preclinical • Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    9d
    From Cell Lines to Avatars: Charting the Future of Preclinical Modeling in T-Cell Malignancies. (PubMed, Cells)
    These "avatar" models preserve vital tumor heterogeneity and microenvironmental context, offering superior predictive value. The systematic development and integration of these next-generation models are essential to bridge the translational gap and advance precision medicine for all patients with T-cell malignancies.
    Preclinical • Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • NOTCH1 (Notch 1)
    |
    NPM1 mutation • ALK fusion
    9d
    A Cold Case: Cold Agglutinin Disease Complicating Stem Cell Transplant. (PubMed, Case Rep Transplant)
    A subsequent CD34-selected stem cell boost from the same donor on Day +108 posttransplant, confirmed to be CAS-negative, resulted in successful platelet engraftment and recovery. This case highlights the potential complications of CAS in donors, emphasizing the need for comprehensive donor evaluation and management strategies to mitigate adverse effects on recipients.
    Journal
    |
    CD34 (CD34 molecule)
    9d
    Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models. (PubMed, Cell Stem Cell)
    Furthermore, a single low-dose infusion of CAR-iNKP cells following conventional chemotherapy reduced minimal residual disease and significantly prevented cancer relapse in human CD19+ B-ALL and CD7+ T-ALL tumor-bearing animals. CAR-iNKP cell treatment addresses the limitations of traditional CAR-NK cell infusion and offers a new strategy for future application in human cancer therapy.
    Journal • Minimal residual disease
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD7 (CD7 Molecule)
    10d
    ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, ECOG-ACRIN Cancer Research Group | N=74 --> 40 | Trial primary completion date: Dec 2025 --> Jul 2025
    Enrollment change • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)
    11d
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV